Practical, IP-minded formulations for ophthalmic and injectables—without “research-project” complexity. We solve solubility, PK, tolerability, and sterile filtration problems so programs move faster.
Many CDMOs & CROs lack the specialized expertise to tackle challenging molecules like hydrophobic APIs, resulting in off-target formulations that miss the mark for ophthalmic and injectable needs. We enable the delivery of poorly water-soluble APIs—hitting target strength, sterile filterability, and exposure without “research-project” complexity.
As inventors of Apisolex™—a clinical-stage, injectable-grade, polyamino-acid polymer platform for poorly soluble APIs—our founders translate first-principles insight into practical but innovative solutions. This experience anchors our Ophthalmic & Injectable Product Development Expertise: hydrophobic drug delivery, PK enhancing, and IP-minded drug formulations.
Our team’s unique IP experience blends deep formulation science with patent strategy from day one. By integrating formulation science with patent strategy early, every formulation win—PK, tolerability, manufacturability—also builds protectable value. You get formulation that benefit the patient and stand up to diligence.
Callan Pharma provides its partners rapid, comprehensive and cost-effective solutions for their difficult formulation development projects.
Callan Pharma Services, 3802 Spectrum Blvd, Suite 120, Tampa, Florida, 33612
2024 © Callan Pharma Services. Privacy / Accessibility / website by APART
